Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
8
×
biotech
8
×
life sciences
national blog main
san francisco blog main
8
×
san francisco top stories
boston blog main
boston top stories
national
national top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
novartis
cancer
deals
diagnostics
eli lilly
fda
merck
pfizer
roche
abbvie
alder biopharmaceuticals
What
drug
8
×
new
approval
bio
roundup
acquisitions
amgen
biggest
ceo
class
developed
drugs
fda
medicines
migraine
nod
patients
won
advantages
albert
amgen’s
arguments
bar
big
bourla
brings
build
buy
cancer
candidates
carries
cholesterol
commercialized
companies
company
company’s
competitors
crispr
daniel
debut
Language
unset
unknown
Current search:
drug
×
biotech
×
amgen
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines